Summary
Osteosarcomas may show variable differentiation. They are divided into osteoblastic, chondroblastic and fibroblastic subgroups depending on their dominant histological differentiation. The pattern of histological differentiation of osteosarcoma is supposed to have an influence on the response to chemotherapy and in this study the relationship between the differentiation of the tumours and response to chemotherapy was examined in 22 osteosarcomas. For this purpose the nuclear size of tumour cells was determined on imprints and the area of the different ground substances on tumour sections after undecalcified preparation. Tumours with little nuclear polymorphism and those with an area of chondroblastic ground substance of more than 20% in the biopsy showed a poor response to chemotherapy. We conclude from our results that lack of nuclear polymorphism and in particular a large area of chondroblastic ground substances in the biopsy, can be regarded as an unfavourable prognostic factor in the response to primary chemotherapy. A comparison of the area of chondroblastic ground substance in biopsy and resection material proves that the biopsy delivers a representative view of the total area of chondroblastic ground substance for the groups of responder and non-responder. Patients with a large amount of chondroblastic ground substance in the biopsy probably require more aggressive chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Apel R, Delling G, Krumme H, Winkler K, Salzer-Kuntschik M (1985) Nuclear polymorphism in osteosarcomas as a prognostic factor for the effect of chemotherapy. A quantitative study. Virchows Arch A (Pathol Anat) 405:215–223
Dahlin DC (1973) Bone tumors. Charles C. Thomas, Springfield, Illinois
Dahlin DC (1975) Pathology of osteosarcoma. Clin Orthop Rel Res 111:23–32
Dahlin DC, Coventry MB (1967) Osteogenic sarcoma. J Bone Jt Surg 49:101–110
Delling G (1984) Skelettsystem. In: Remmele W (ed) Pathologie. Band 3:639–740
Delling G (1972) Über eine vereinfachte Methacrylatteinbettung für unentkalkte Knochenschnitte. Beitr Pathol 145:100–105
Delling G, Zach W, Alm J (1985) Quantitative Grundsubstanzbestimmung in Osteosarkomen und ihre Bedeutung für das Ansprechen auf eine Polychemotherapie. Verh Dtsch Ges Pathol 69:605
Dominok GW, Knoch HG (1971) Knochengeschwülste und geschwulstähnliche Knochenerkrankungen. VEB Gustav Fischer Verlag, Jena
Garrington GE, Scofield HH, Cornyn J, Hooker SP (1967) Osteosarcoma of the jaws. Cancer 20:377–391
Goidanich IF, Battaglia L, Silva E (1966) Osteogenic sarcoma. Analysis of the factors influencing prognosis in 100 cases. Clin Orthop 48:209–222
Kragh LV, Dahlin DC, Erich JB (1958) Osteogenic sarcoma of the jaws and facial bones. Amer J Surg 96:496–505
Konjetzny GE (1933) Knochensarkome und ihre Begrenzung. Arch Klin Chir 176:335–397
Larsson SE, Lorentzon R, Wedren H, Boquist L (1978) Osteosarcoma. A multifactorial clinical and histopathological study with special regard to therapy and survival. Acta Orthop Scand 49:571–581
McKenna RJ, Schwinn CP, Soong KY, Higinbotham NL (1966) Sarcomata of the osteogenic series (osteosarcoma, fibrosarcoma, chondrosarcoma, parosteal osteogenic sarcoma, and sarcoma arising in abnormal bone). J Bone Jt Surg 48-A:1–26
Ohno T, Abe M, Tateishi A, Kako K, Miki H, Sekine K, Ueyama H, Hasegaw O, Obara K (1975) Osteogenic sarcoma. A study of hundred and thirty cases. J Bone Jt Surg 57-A:397–404
Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230
Salzer-Kuntschik M, Delling G, Sigmund R, Beron G (1983) Morphological grades of regression in osteosarcoma after polychemotherapy COSS 80. J Cancer Clin Oncol 106:21–24
Schajowicz F, Ackerman LV, Sissons HA (1972) Histological typing of bone tumors. WHO, Genf
Spjut HJ, Dorfman HD, Fechner RE, Ackerman V (1971) Tumors of bone and cartilage. Atlas of bone pathology AFIP, Washington
Unni KK, Dahlin DC, Beabout JW, Ivins JC (1976) Parosteal osteogenic sarcoma. Cancer 37:2644–2675
Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, Brandeis W, Ebell W, Erttmann R, Göbel U, Havers W, Henze G, Hinderfeld L, Höcker P, Jobke A, Jürgens H, Kabisch H, Preusser P, Prindull G, Ramach W, Ritter J, Sekera J, Treuner J, Wüst G, Landbeck G (1984) Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German/Austrian Study, J Clin Oncol 2:617–624
Winkler K, Beron G, Purfürst C, Berger J, Delling G, Gerein V, Graf N, Jürgens H, Kotz R, Ritter J, Russe W (1986) Conclusions from the Cooperative Osteosarcoma (OS) Studies COSS-80 and COSS-82 for future therapeutic strategies. J Cancer Clin Oncol (Suppl) 111:7
Weinfeld MS, Dudley HR (1962) Osteogenic sarcoma. A follow-up study of the ninety-four cases observed at the Massachusetts general hospital from 1920 to 1960. J Bone Jt Surg 44-A:269–276
Author information
Authors and Affiliations
Additional information
This work was supported by Hamburger Landesverband für Krebsbekämpfung e.V.
Rights and permissions
About this article
Cite this article
Kersjes, W., Heise, U., Winkler, K. et al. Comparison of quantitative ground substance analysis in biopsy and resected tumour in osteosarcomas*. Vichows Archiv A Pathol Anat 412, 155–160 (1987). https://doi.org/10.1007/BF00716188
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00716188